Estimaciones de analistas de Wall Street para Fulgent Genetics, Inc. (FLGT): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 6 |
| Mantener | 3 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 9 |
| Calificación media (1-5) | 0.67 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-06 | $-0.65 | ||
| 2026-07-30 | $-0.58 | $-0.46 | -26.1% |
| 2026-05-01 | $-0.36 | $-0.35 | -3.4% |
| 2026-02-27 | $0.16 | $0.03 | +433.3% |
| 2025-11-07 | $0.14 | $-0.24 | +158.3% |
| 2025-08-01 | $0.07 | $-0.23 | +130.4% |
| 2025-05-02 | $0.04 | $-0.19 | +121.1% |
| 2025-02-28 | $0.04 | $-0.31 | +112.9% |
Ratios de valoración
| Precio / Valor contable | 0.60 |
| EV / EBITDA | -8.36 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $18.3M | $18.7M | $21.4M | $32.5M | $421.7M | $992.6M | $619.0M | $289.2M | $283.5M | $322.7M |
| Coste de Ventas | $6.7M | $8.6M | $10.7M | $14.1M | $89.8M | $215.5M | $252.1M | $184.8M | $176.3M | $191.8M |
| Beneficio Bruto | $11.6M | $10.2M | $10.7M | $18.4M | $331.9M | $777.1M | $366.9M | $104.5M | $107.2M | $130.9M |
| I+D | $3.6M | $4.2M | $5.5M | $6.5M | $11.6M | $24.2M | $28.9M | $41.4M | $48.8M | $53.9M |
| Generales y Administrativos | $7.1M | $9.4M | $10.2M | $12.3M | $30.2M | $75.2M | $150.0M | $130.5M | $124.4M | $160.0M |
| Gastos Operativos | $10.6M | $13.6M | $15.7M | $18.8M | $41.7M | $101.1M | $188.4M | $300.0M | $181.1M | $222.0M |
| Beneficio Operativo | $919000 | -$3.5M | -$5.1M | -$428000 | $290.2M | $676.0M | $178.5M | -$195.5M | -$73.9M | -$91.1M |
| EBITDA | $2.1M | -$1.8M | -$2.9M | $1.7M | $293.1M | $692.0M | $217.7M | -$147.5M | -$26.9M | -$45.8M |
| Gastos por Intereses | $5.4M | 0 | 0 | 0 | 0 | 0 | $1.0M | $488000 | $170000 | $75000 |
| Beneficio Antes de Impuestos | -$4.5M | -$3.0M | -$4.6M | -$368000 | $286.8M | $681.0M | $184.0M | -$174.1M | -$52.0M | -$70.0M |
| Impuestos | $920000 | -$1.0M | $36000 | $43000 | $72.5M | $174.8M | $42.1M | $1.2M | -$8.1M | -$8.4M |
| Beneficio Neto | -$5.3M | -$2.5M | -$5.6M | -$411000 | $214.3M | $507.4M | $143.4M | -$167.8M | -$42.7M | -$60.5M |
| BPA | $-0.30 | $-0.15 | $-0.25 | $-0.02 | $9.44 | $17.13 | $4.76 | $-5.63 | $-1.41 | $-1.97 |
| BPA Diluido | $-0.30 | $-0.15 | $-0.25 | $-0.02 | $8.91 | $16.26 | $4.63 | $-5.63 | $-1.41 | $-1.97 |
| Acciones en Circulación (Diluidas) | $17.7M | $17.7M | $18.0M | $18.7M | $24.1M | $31.0M | $31.0M | $29.8M | $30.2M | $30.8M |
Precio
| Precio | $21.63 |
| Capitalización | $614M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ARVN · AVXL · BFLY · CDNA · CSTL · DRIO · MYGN
Explorar sector: Healthcare · Medical - Diagnostics & Research
Más secciones de FLGT: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones